<?xml version="1.0" encoding="UTF-8"?>
<p>Given that there is still no vaccine available for use in humans, the treatment of leishmaniasis mainly depends on chemotherapy. However, there has been development of resistance toward first line drugs. In addition, the second line drugs have severe adverse effects and are costly in resource-limited areas.
 <xref rid="cit0007" ref-type="bibr">7</xref> This urges the demand for new antileishmanial agents to prevent and treat this disease. Moreover, researchersâ€™ attention is being drawn toward naturally derived compounds used to treat parasitic diseases including leishmaniasis for identification of new lead compounds and/or new drugs against the disease which warrant investigation.
 <xref rid="cit0008" ref-type="bibr">8</xref>
</p>
